Cormorant Asset Management LP 13D and 13G filings for Ambrx Biopharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-03-13 4:00 pm Purchase | 2023-03-03 | 13G | Ambrx Biopharma Inc. AMAM | Cormorant Asset Management LP | 52,500,000 17.730% | 36,145,298 (+221.01%) | Filing |
| 2023-02-14 3:12 pm Sale | 2022-12-31 | 13G | Ambrx Biopharma Inc. AMAM | Cormorant Asset Management LP | 16,354,702 6.050% | -911,442 (-5.28%) | Filing |
| 2022-02-14 3:09 pm Sale | 2021-12-31 | 13G | Ambrx Biopharma Inc. AMAM | Cormorant Asset Management LP | 17,266,144 7.060% | -138,558 (-0.80%) | Filing |
| 2021-07-02 4:12 pm Purchase | 2021-06-22 | 13G | Ambrx Biopharma Inc. AMAM | Cormorant Asset Management LP | 17,404,702 6.600% | 17,404,702 (New Position) | Filing |